Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

Authors


Prof K. J. Pasi, Chairman of the UKHCDO von Willebrand Disease Working Party, Department of Haematology, Barts and The London, Queen Mary's School of Medicine and Dentistry, Turner Street, London E1 2AD, UK.
Tel.: +44 20 7377 7000 (x) 3152; fax: +44 709 222 7649;
e-mail: k.j.pasi@qmul.ac.uk.

Abstract

Summary.  von Willebrand disease (VWD) is the commonest inherited bleeding disorder. The aim of therapy for VWD is to correct the two defects of haemostasis in this disorder, impaired primary haemostasis because of defective platelet adhesion and aggregation and impaired coagulation as a result of low levels of factor VIII. The objective of this guideline is to inform individuals making choices about the treatment and management of VWD including the use of therapeutic products. This is the second edition of this UK Haemophilia Centre Doctors' Organization (UKHCDO) guideline and supersedes the previous edition which was published in 1994.

Ancillary